Ferring Pharmaceuticals SA, of Saint Prex, Switzerland, said it has acquired the assets of Biosurface Engineering Technologies Inc., including two phase III ready orthobiologic product candidates designed to improve bone repair. The initial indications for Amplex and Prefix to be investigated are fusion in foot/ankle and lumbar spine surgical procedures, respectively.